# Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)

> **NCT00806585** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 620 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Hypertension

## Interventions

- **DRUG:** MK-0736
- **DRUG:** Comparator: Placebo
- **DRUG:** Comparator: HCTZ

## Key facts

- **NCT ID:** NCT00806585
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2010-03
- **Final completion:** 2010-06
- **Target enrollment:** 620 (ACTUAL)
- **Last updated:** 2015-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00806585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00806585, "Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT00806585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*